Glioblastoma Cells with Adaptive Temozolomide Resistance andAbsent MGMT Expression Exhibit Enhanced Susceptibility to Zika Virus Oncolysis

Abstract Purpose Glioblastoma (GBM) resistance to temozolomide (TMZ) is a major barrier to durable disease control, and oncolytic virotherapy with Zika virus (ZIKV) has emerged as an alternative. However, given that host DNA damage response (DDR) appears to modulate virotherapy efficacy, whether ZIKV remains effective under TMZ resistance and its molecular determinants are open questions. We investigated the interplay between TMZ resistance and ZIKV infection in GBM, evaluating MGMT, the strongest clinical predictor of TMZ response and principal determinant of alkylation-damage repair, as a candidate shared determinant. Methods Six GBM cell lines were exposed to escalating TMZ doses to model acquired chemoresistance and characterized for ZIKV replication and induced cell death. Transcriptomic profiling, RT-qPCR, and pharmacological MGMT inhibition interrogated mechanistic links between DNA repair and viral susceptibility. Findings were validated in patient-derived organoids from two donors with discordant patterns of MGMT expression. Results Cells from four out of six GBM lines proliferated in vitro throughout TMZ exposure; U251 and U87 cells acquired resistance (adaptive, ADA), while U138 and LN18 cells showed unchanged IC50 (non-adaptive, N-ADA). Although acquisition of TMZ resistance did not alter susceptibility to ZIKV oncolysis, remarkably, ADA lines were more susceptible to ZIKV-induced death and supported higher viral replication than N-ADA lines. ADA cells lacked MGMT expression and showed basal depletion of DNA repair programmes, while N-ADA cells expressed both. Pharmacological MGMT inhibition sensitized N-ADA LN18 cells to ZIKV with concurrent γH2AX accumulation, supporting a contributing role for MGMT-dependent repair. This dichotomy was recapitulated in ZIKV infection assays with patient-derived GBM organoids displaying opposite patterns of MGMT expression. Conclusion MGMT status may be a common indicator of TMZ or ZIKV response in GBM, supporting its use for future rational combination ZIKV virotherapy tailored to patient MGMT expression.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11445943/v1
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Glioblastoma Cells with Adaptive Temozolomide Resistance andAbsent MGMT Expression Exhibit Enhanced Susceptibility to Zika Virus Oncolysis

Elisa Helena Farias Jandrey, Oswaldo Keith Okamoto, Letícia Jordão Marques de Oliveira, Miyuki Uno et al.
1 links
Research Square
Glioma Diagnosis and Treatment
preprint

Glioblastoma Cells with Adaptive Temozolomide Resistance andAbsent MGMT Expression Exhibit Enhanced Susceptibility to Zika Virus Oncolysis

Elisa Helena Farias Jandrey, Oswaldo Keith Okamoto, Letícia Jordão Marques de Oliveira, Miyuki Uno, Maria José Ferreira Alves, Alice Kei Endo, Isabela Fonseca de Oliveira Granha, Roger J. Chammas, Gustavo Sartorelli, Iuri Santana Neville, Brandow Willy, Desirée Plaça
preprint en

Abstract

Abstract Purpose Glioblastoma (GBM) resistance to temozolomide (TMZ) is a major barrier to durable disease control, and oncolytic virotherapy with Zika virus (ZIKV) has emerged as an alternative. However, given that host DNA damage response (DDR) appears to modulate virotherapy efficacy, whether ZIKV remains effective under TMZ resistance and its molecular determinants are open questions. We investigated the interplay between TMZ resistance and ZIKV infection in GBM, evaluating MGMT, the strongest clinical predictor of TMZ response and principal determinant of alkylation-damage repair, as a candidate shared determinant. Methods Six GBM cell lines were exposed to escalating TMZ doses to model acquired chemoresistance and characterized for ZIKV replication and induced cell death. Transcriptomic profiling, RT-qPCR, and pharmacological MGMT inhibition interrogated mechanistic links between DNA repair and viral susceptibility. Findings were validated in patient-derived organoids from two donors with discordant patterns of MGMT expression. Results Cells from four out of six GBM lines proliferated in vitro throughout TMZ exposure; U251 and U87 cells acquired resistance (adaptive, ADA), while U138 and LN18 cells showed unchanged IC50 (non-adaptive, N-ADA). Although acquisition of TMZ resistance did not alter susceptibility to ZIKV oncolysis, remarkably, ADA lines were more susceptible to ZIKV-induced death and supported higher viral replication than N-ADA lines. ADA cells lacked MGMT expression and showed basal depletion of DNA repair programmes, while N-ADA cells expressed both. Pharmacological MGMT inhibition sensitized N-ADA LN18 cells to ZIKV with concurrent γH2AX accumulation, supporting a contributing role for MGMT-dependent repair. This dichotomy was recapitulated in ZIKV infection assays with patient-derived GBM organoids displaying opposite patterns of MGMT expression. Conclusion MGMT status may be a common indicator of TMZ or ZIKV response in GBM, supporting its use for future rational combination ZIKV virotherapy tailored to patient MGMT expression.

Research Square
Universidade de São Paulo (BR), Stanford University (US)
Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Universidade de São Paulo
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon